Sonnet Biotherapeutics Holdings, INC 8-K filings

Hyperliquid Strategies Inc. (HSI) has completed its business combination with Sonnet BioTherapeutics Holdings, Inc., with HSI common stock set to trade on Nasdaq under 'PURR'.

Sonnet BioTherapeutics Holdings, Inc. announced its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.

Sonnet BioTherapeutics Holdings, Inc. adjourned its special meeting of stockholders to December 2, 2025, seeking more votes for its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.

Sonnet BioTherapeutics Holdings, Inc. stockholders approved all four proposals, including director elections and auditor ratification, at their Annual Meeting on September 26, 2025.

Sonnet BioTherapeutics Holdings, Inc. has entered into a formal employment agreement with interim Chief Executive Officer Raghu Rao, outlining his base salary, performance bonuses, and severance terms.

Sonnet BioTherapeutics Holdings, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a successful private placement and warrant exercises totaling approximately $16 million.

Sonnet Biotherapeutics Holdings, Inc. announced it has raised approximately $16 million through a private placement and warrant exercises, believing it has regained compliance with Nasdaq's minimum stockholders' equity requirement.

Sonnet BioTherapeutics Holdings, Inc. has entered into a definitive agreement for a business combination with Rorschach I LLC, forming Hyperliquid Strategies Inc. (HSI), which will pivot to a cryptocurrency treasury strategy focused on HYPE tokens, valued at an estimated $888 million at closing.

Sonnet BioTherapeutics Holdings, Inc. has completed a private placement of $2.0 million in convertible notes and associated warrants, aiming to bolster its financial position and potentially facilitate future capital raises.

Sonnet BioTherapeutics Holdings, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting if compliance is not regained.

Sonnet BioTherapeutics reports positive safety data for SON-1010 combined with atezolizumab in a Phase 1b/2a trial, allowing the study to proceed to the expansion phase.

Sonnet BioTherapeutics reports the passing of its CEO, Pankaj Mohan, and the subsequent appointment of Raghu Rao as interim CEO and promotion of Stephen McAndrew to President and Chief Business Officer.

Sonnet BioTherapeutics reports positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical trial evaluating SON-1010 in combination with trabectedin for advanced leiomyosarcoma or liposarcoma.

Sonnet BioTherapeutics has been granted a second patent by the USPTO for its IL-18 variant protein, potentially opening licensing opportunities and strengthening its intellectual property position.

Sonnet BioTherapeutics presented data at the AACR IO Conference showcasing the potential of SON-1010, a novel immunotherapeutic, as a monotherapy or in combination to improve solid tumor treatment.

Sonnet BioTherapeutics is making its Antibody Drug Conjugate (ADC) platform available for drug discovery partnerships, aiming to generate multiple pipeline drug candidates.

Sonnet BioTherapeutics announced its financial results for the three months ended December 31, 2024, and provided a business update, highlighting progress in clinical trials and strategic partnerships.

Sonnet BioTherapeutics has been granted a European patent for its Fully Human Albumin Binding (FHAB) technology, further solidifying its global intellectual property position.

Sonnet BioTherapeutics is expanding its Phase 1 SB101 trial to evaluate the combination of SON-1010 with trabectedin in certain sarcomas, following positive monotherapy data.

Sonnet BioTherapeutics announced its fiscal year 2024 financial results, showcasing a significant reduction in operating expenses and continued progress in its clinical programs.

Sonnet BioTherapeutics has successfully raised approximately $3.9 million through a registered direct offering and a concurrent private placement, both priced at-the-market.

Sonnet BioTherapeutics reports successful completion of the SON-1010 monotherapy dose escalation in a Phase 1 trial, with a maximum tolerated dose established and promising signs of clinical benefit.

Sonnet BioTherapeutics announced the publication of extensive preclinical data on SON-1010, highlighting its unique mechanism of action in targeting tumors.

Sonnet BioTherapeutics has announced the pricing of a $5 million underwritten public offering to support research and development, clinical trials, working capital, and debt repayment.

Sonnet BioTherapeutics has been granted a U.S. patent for a modified version of IL-18, incorporated into two new immunotherapeutic drug candidates designed to enhance cancer treatment.

Sonnet BioTherapeutics has regained compliance with Nasdaq's minimum bid price requirement, avoiding potential delisting.

Sonnet BioTherapeutics has granted Alkem Laboratories exclusive rights to develop and commercialize SON-080 for diabetic peripheral neuropathy and other neuropathies in India.

Sonnet BioTherapeutics has completed a one-for-eight reverse stock split of its common stock, effective September 30, 2024.

Sonnet BioTherapeutics has completed enrollment and initiated dosing in its Phase 1 clinical trial of SON-1010 for adult patients with advanced solid tumors, with topline data expected in Q4 2024.

Sonnet BioTherapeutics' stockholders approved the election of directors, a stock issuance, a reverse stock split, and the ratification of their accounting firm at their annual meeting on September 12, 2024.